
Opinion|Videos|February 27, 2025
PEACE-3 study of enzalutamide + Ra-223 for ARPI-naïve mCRPC: Design and objectives
Author(s)Abhishek Tripathi, MD
An expert discusses the design and objectives of the PEACE-3 study, which investigates the combination of enzalutamide and radium-223 for ARPI-naïve metastatic castration-resistant prostate cancer (mCRPC).
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
2
FDA Accepts NDA of Zanzalintinib Combo for Pretreated Metastatic CRC
3
Dr Shubham Pant Highlights Progress and Promise in Pancreatic Cancer Treatment
4
New Phase 2 Study of Tri-Modal Immunotherapy for Indolent B-Cell Lymphoma Launches
5



















